Aptorum Group GAAP EPS of -$1.60
Seeking Alpha News (Fri, 21-Aug 5:10 PM ET)
Niki BioSolutions Expands Precision Medicine Footprint with APOE Genotyping Partnership
Market Chameleon (Thu, 23-Jul 4:38 AM ET)
Globe Newswire (Thu, 23-Jul 8:00 AM ET)
Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).
Niki Biosolutions trades on the NASDAQ stock market under the symbol NIKI.
As of August 21, 2026, NIKI stock price climbed to $8.58 with 30,322 million shares trading.
NIKI has a market cap of $6.99 million. This is considered a Sub-Micro Cap stock.
NIKI support price is $7.41 and resistance is $8.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NIKI shares will trade within this expected range on the day.